Differences of cyclin-dependent kinase 4/6 inhibitor, palbociclib and abemaciclib, in breast cancer

Area of Science:

• Oncology
• Pharmacology

Background:

• Palbociclib and abemaciclib are oral, selective inhibitors of cyclin-dependent kinase 4 and 6 (CDK4/6).
• These CDK4/6 inhibitors have demonstrated significant progression-free survival improvements in hormone receptor-positive, HER2-negative metastatic breast cancer when combined with endocrine therapy.

Purpose of the Study:

• To review and compare palbociclib and abemaciclib, two approved CDK4/6 inhibitors in Japan.
• To highlight differences in efficacy based on patient subsets and side effect profiles for optimal clinical application.

Main Methods:

• Review of pivotal phase III trials (PALOMA and MONARCH) for palbociclib and abemaciclib.
• Analysis of subset data to identify patient characteristics associated with differential clinical benefits.
• Comparison of safety profiles, including adverse events like neutropenia, diarrhea, nausea, and liver dysfunction.

Main Results:

• Both palbociclib and abemaciclib offer significant benefits in metastatic breast cancer treatment.
• Palbociclib benefits are associated with bone-only disease, no measurable disease, endocrine-sensitive disease, and longer disease-free intervals.
• Abemaciclib shows benefits in visceral disease, liver metastasis, endocrine-resistant disease, and shorter treatment-free intervals. Abemaciclib also induces senescence and apoptosis more effectively than palbociclib.

Conclusions:

• Palbociclib and abemaciclib exhibit comparable overall benefits but differ in patient subset applicability and side effect profiles.
• Understanding these distinctions is crucial for informed clinical decision-making in managing metastatic breast cancer.
• Abemaciclib's distinct mechanism and side effect profile may offer advantages in specific patient populations.